Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PADCEV vs CLOFARABINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Enfortumab vedotin is an antibody-drug conjugate (ADC) directed against Nectin-4, a cell adhesion molecule expressed on urothelial carcinoma cells. The antibody portion binds to Nectin-4, leading to internalization and release of the microtubule-disrupting agent monomethyl auristatin E (MMAE) via proteolytic cleavage. MMAE binds to tubulin and inhibits microtubule polymerization, inducing G2/M phase arrest and apoptosis.
Clofarabine is a purine nucleoside antimetabolite that inhibits DNA synthesis by reducing intracellular deoxynucleotide triphosphate pools via inhibition of ribonucleotide reductase, and by terminating DNA chain elongation through incorporation into DNA, leading to apoptosis.
FDA-approved: Treatment of adult patients with locally advanced or metastatic urothelial carcinoma who have received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and a platinum-containing chemotherapy.,Off-label: None established.
Treatment of relapsed or refractory acute lymphoblastic leukemia (ALL) in pediatric patients aged 1 to 21 years,Off-label: Treatment of acute myeloid leukemia (AML), myelodysplastic syndromes (MDS)
1.25 mg/kg (up to 125 mg) intravenously on days 1, 8, and 15 of a 28-day cycle
52 mg/m^2 intravenously over 2 hours daily for 5 consecutive days, repeated every 28 days.
Approximately 3.4 days (range 2.8-4.2 days) at steady state, supporting every-3-week dosing. Terminal half-life consistent with Ig G1 clearance.
Terminal elimination half-life: 5.2 hours (range 4-6 hours) in adult patients; clinically, this supports a 5-day continuous infusion schedule
The small molecule MMAE is metabolized primarily by CYP3A4. Enfortumab, the antibody component, is catabolized to small peptides and amino acids.
Hepatic; primarily metabolized by deamination via cytidine deaminase to 6-ketoclofarabine, a major metabolite. Also undergoes phosphorylation intracellularly. CYP450 involvement is minimal.
Primarily metabolized via catabolism into small peptides and amino acids; minimal renal excretion (<5% unchanged drug in urine). No biliary/fecal data available.
Renal: 49-60% as unchanged drug; biliary/fecal: minimal (<1%)
No specific protein binding data; as a monoclonal antibody, it is not highly bound to plasma proteins (expected <10%).
47% bound to plasma proteins (primarily albumin)
Approximately 0.07 L/kg (7.0 L in 70 kg patient), indicating limited extravascular distribution and consistent with distribution into vascular and interstitial spaces.
Vd: 14.6 L/kg (range 10-20 L/kg); indicates extensive extravascular distribution and tissue binding
Administered intravenously only; bioavailability 100% by IV route.
IV: 100% (only IV route); oral: not approved
No dose adjustment recommended for mild to moderate renal impairment (e GFR ≥30 m L/min/1.73m2). Use not recommended in severe renal impairment (e GFR <30 m L/min/1.73m2) or ESRD.
Clcr ≥ 60 m L/min: no adjustment; Clcr 30-59 m L/min: reduce dose to 39 mg/m^2; Clcr < 30 m L/min: not recommended (no data).
No formal studies; mild (Child-Pugh A) and moderate (Child-Pugh B) may use with caution; not recommended in severe (Child-Pugh C).
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25% (monitor toxicity); Child-Pugh C: not recommended (no data).
Safety and effectiveness in pediatric patients have not been established.
52 mg/m^2 intravenously over 2 hours daily for 5 days every 28 days (same as adult dosing per body surface area; safety and efficacy established in pediatric patients 1 year and older).
No specific dose adjustment recommended based on age alone; monitor closely for adverse effects due to potential comorbidities and polypharmacy.
No specific dose adjustment based solely on age; monitor renal function closely due to increased risk of nephrotoxicity; use same dosing as adults with renal adjustment as per GFR.
WARNING: SERIOUS SKIN REACTIONS. PADCEV can cause severe, life-threatening or fatal cutaneous adverse reactions including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). Discontinue PADCEV immediately if signs or symptoms of SJS or TEN occur and permanently discontinue if confirmed.
Clofarabine causes severe bone marrow suppression, including neutropenia, anemia, thrombocytopenia, and increased risk of infection. Hemorrhage and severe infections have been reported. Monitor blood counts regularly.
Cutaneous adverse reactions: Monitor for severe skin reactions; interrupt or discontinue as appropriate.,Hyperglycemia: Monitor blood glucose levels, especially in patients with diabetes or risk factors; manage with antihyperglycemics.,Ocular disorders: May cause keratitis, dry eye, or blurred vision; monitor and refer to ophthalmologist.,Peripheral neuropathy: Monitor for new or worsening neuropathy; dose adjustment may be required.,Pneumonitis or interstitial lung disease: Monitor for signs and symptoms; discontinue if confirmed.
1) Myelosuppression: monitor CBCs; dose adjustment may be needed. 2) Infections: increased susceptibility. 3) Hemorrhagic cystitis: may occur; manage with hydration and monitoring. 4) Hepatic toxicity: monitor liver function tests; dose reduction in hepatic impairment. 5) Renal toxicity: monitor renal function; dose adjustment for creatinine clearance <60 m L/min. 6) Tumor lysis syndrome: hydrate and use prophylactic allopurinol. 7) Systemic inflammatory response syndrome (SIRS): monitor for signs; discontinue if occurs.
None.
Hypersensitivity to clofarabine or any component of the formulation; severe hepatic impairment (Child-Pugh class C); severe renal impairment (creatinine clearance <30 m L/min).
No specific food interactions reported. However, patients should maintain adequate hydration. Avoid grapefruit and grapefruit juice if taking concurrent CYP3A4 substrates.
Grapefruit and grapefruit juice may affect liver enzymes and should be avoided. No specific food restrictions, but avoid alcohol due to potential hepatotoxicity. Maintain adequate hydration; no other known food interactions.
PADCEV (enfortumab vedotin) is a pregnancy category D drug. Based on its mechanism of action (MMAE-mediated disruption of microtubules), there is a potential risk of fetal harm. Advise pregnant women of the potential risk to the fetus. First trimester: Highest risk of major congenital malformations. Second and third trimesters: Risk of fetal growth restriction and oligohydramnios due to MMAE's anti-mitotic effects.
Clofarabine is embryotoxic and teratogenic in animal studies. In humans, it is classified as Pregnancy Category D. First trimester exposure is associated with major congenital malformations including neural tube defects, skeletal anomalies, and cardiovascular defects. Second and third trimester exposure may cause fetal myelosuppression, intrauterine growth restriction, and premature delivery.
No data on presence of enfortumab vedotin or its metabolites in human milk. M/P ratio unknown. Because many drugs are excreted in human milk and due to potential for serious adverse reactions in nursing infants, advise women not to breastfeed during treatment and for at least 3 weeks after the last dose.
It is unknown whether clofarabine is excreted in human breast milk. Due to the potential for serious adverse reactions in nursing infants, breastfeeding is contraindicated during therapy and for at least 1 week after the last dose. M/P ratio is not available.
No specific dose adjustments are recommended due to lack of pharmacokinetic data in pregnancy. The drug should be avoided during pregnancy unless the benefit outweighs risks. Physiologic changes in pregnancy (increased volume of distribution, renal clearance) may reduce exposure, but no dose adjustment guidelines exist.
No specific pharmacokinetic studies have been conducted in pregnant women. Dose adjustments based on pregnancy-induced physiologic changes (increased plasma volume, renal clearance) are not established. Use with caution; the lowest effective dose based on tolerability and clinical response is recommended. Close monitoring for toxicity is essential.
PADCEV (enfortumab vedotin-ejfv) is a Nectin-4-directed antibody-drug conjugate used in locally advanced or metastatic urothelial carcinoma. Monitor for peripheral neuropathy, skin reactions, and hyperglycemia. Premedicate with antihistamines and antipyretics to reduce infusion reactions. Dose reductions may be needed for Grade 3 or higher adverse events.
Clofarabine is a purine nucleoside antimetabolite used primarily in pediatric relapsed or refractory acute lymphoblastic leukemia (ALL). It is associated with significant myelosuppression; monitor absolute neutrophil count and platelets closely. Capillary leak syndrome and systemic inflammatory response syndrome (SIRS) are rare but serious adverse effects; consider prophylactic corticosteroids. Hepatic veno-occlusive disease (VOD) has been reported, especially in patients with prior stem cell transplant. Administer with adequate hydration and monitor for tumor lysis syndrome.
Report any new or worsening numbness, tingling, or pain in hands or feet immediately.,Monitor for signs of skin reactions such as rash, itching, or blisters, and avoid sun exposure.,Check blood glucose regularly if you have diabetes or are at risk for hyperglycemia.,Use effective contraception during treatment and for at least 2 weeks after the last dose.,Avoid live vaccines during treatment.
Clofarabine is a chemotherapy drug that may lower your blood cell counts, increasing risk of infection, bleeding, and fatigue.,Report any signs of infection (fever, chills, sore throat), unusual bleeding or bruising, or shortness of breath immediately.,Drink plenty of fluids (8-10 glasses per day) to prevent kidney problems and tumor lysis syndrome.,Avoid live vaccines and close contact with people who have recently received oral polio vaccine.,Use effective contraception during treatment and for at least 6 months after the last dose.,Do not breastfeed while taking clofarabine.,You may experience nausea, vomiting, or diarrhea; your doctor can prescribe medications to manage these symptoms.
No interactions on record
"Clofarabine, a purine nucleoside antimetabolite used in hematologic malignancies, may reduce the metabolism of Eltrombopag, a thrombopoietin receptor agonist, via inhibition of UDP-glucuronosyltransferase (UGT) enzymes, particularly UGT1A1 and UGT1A3. This leads to increased systemic exposure of Eltrombopag, potentially elevating the risk of hepatotoxicity (e.g., elevated liver enzymes) and other adverse effects such as thrombosis. Clinical outcomes may include exacerbated liver injury, which is particularly concerning in patients with pre-existing hepatic impairment or those receiving other hepatotoxic agents."
"Concurrent use of clofarabine and mecamylamine may synergistically increase the risk of severe hypotension and syncope. Clofarabine is a purine nucleoside analog that can cause capillary leak syndrome and hypotension, while mecamylamine is a ganglionic blocker that inhibits sympathetic outflow, leading to orthostatic hypotension. The combined hypotensive effects may result in profound blood pressure reduction, dizziness, and potential falls, particularly in patients with impaired cardiovascular function."
"The combination of clofarabine and nifedipine may increase the risk of cardiotoxicity, particularly QT interval prolongation and left ventricular dysfunction. Clofarabine has been associated with pericardial effusion and cardiac tamponade, while nifedipine, a calcium channel blocker, can cause hypotension and reflex tachycardia, potentially compounding hemodynamic stress in patients with compromised cardiac function. Clinical outcomes may include arrhythmias, heart failure exacerbation, or sudden cardiac death, especially in patients with preexisting cardiovascular risk factors."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PADCEV vs CLOFARABINE, answered by our medical review team.
PADCEV is a Antineoplastic Agent that works by Enfortumab vedotin is an antibody-drug conjugate (ADC) directed against Nectin-4, a cell adhesion molecule expressed on urothelial carcinoma cells. The antibody portion binds to Nectin-4, leading to internalization and release of the microtubule-disrupting agent monomethyl auristatin E (MMAE) via proteolytic cleavage. MMAE binds to tubulin and inhibits microtubule polymerization, inducing G2/M phase arrest and apoptosis.. CLOFARABINE is a Antineoplastic Agent that works by Clofarabine is a purine nucleoside antimetabolite that inhibits DNA synthesis by reducing intracellular deoxynucleotide triphosphate pools via inhibition of ribonucleotide reductase, and by terminating DNA chain elongation through incorporation into DNA, leading to apoptosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PADCEV and CLOFARABINE depend on the specific clinical indication. These are both Antineoplastic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PADCEV is: 1.25 mg/kg (up to 125 mg) intravenously on days 1, 8, and 15 of a 28-day cycle. The standard adult dose of CLOFARABINE is: 52 mg/m^2 intravenously over 2 hours daily for 5 consecutive days, repeated every 28 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PADCEV and CLOFARABINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PADCEV is classified as Category C. PADCEV (enfortumab vedotin) is a pregnancy category D drug. Based on its mechanism of action (MMAE-mediated disruption of microtubules), there is a potential risk of fetal harm. Ad. CLOFARABINE is classified as Category C. Clofarabine is embryotoxic and teratogenic in animal studies. In humans, it is classified as Pregnancy Category D. First trimester exposure is associated with major congenital malf. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.